Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion.

Furugaki K, Mochizuki M, Kohno M, Shu S, Harada N, Yoshimura Y.

BMC Cancer. 2019 Apr 3;19(1):301. doi: 10.1186/s12885-019-5527-2.

2.

Molecular targeting of HER2-overexpressing biliary tract cancer cells with trastuzumab emtansine, an antibody-cytotoxic drug conjugate.

Yamashita-Kashima Y, Yoshimura Y, Fujimura T, Shu S, Yanagisawa M, Yorozu K, Furugaki K, Higuchi R, Shoda J, Harada N.

Cancer Chemother Pharmacol. 2019 Apr;83(4):659-671. doi: 10.1007/s00280-019-03768-8. Epub 2019 Jan 18.

PMID:
30659304
3.

Alectinib Resistance in ALK-Rearranged Lung Cancer by Dual Salvage Signaling in a Clinically Paired Resistance Model.

Tsuji T, Ozasa H, Aoki W, Aburaya S, Funazo T, Furugaki K, Yoshimura Y, Ajimizu H, Okutani R, Yasuda Y, Nomizo T, Uemasu K, Hasegawa K, Yoshida H, Yagi Y, Nagai H, Sakamori Y, Ueda M, Hirai T, Kim YH.

Mol Cancer Res. 2019 Jan;17(1):212-224. doi: 10.1158/1541-7786.MCR-18-0325. Epub 2018 Aug 31.

PMID:
30171175
4.

Increased EGFR Phosphorylation Correlates with Higher Programmed Death Ligand-1 Expression: Analysis of TKI-Resistant Lung Cancer Cell Lines.

Suda K, Rozeboom L, Furugaki K, Yu H, Melnick MAC, Ellison K, Rivard CJ, Politi K, Mitsudomi T, Hirsch FR.

Biomed Res Int. 2017;2017:7694202. doi: 10.1155/2017/7694202. Epub 2017 Oct 8.

5.

Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model.

Masuda C, Yanagisawa M, Yorozu K, Kurasawa M, Furugaki K, Ishikura N, Iwai T, Sugimoto M, Yamamoto K.

Int J Oncol. 2017 Aug;51(2):425-434. doi: 10.3892/ijo.2017.4036. Epub 2017 Jun 8.

6.

Impact of bevacizumab in combination with erlotinib on EGFR-mutated non-small cell lung cancer xenograft models with T790M mutation or MET amplification.

Furugaki K, Fukumura J, Iwai T, Yorozu K, Kurasawa M, Yanagisawa M, Moriya Y, Yamamoto K, Suda K, Mizuuchi H, Mitsudomi T, Harada N.

Int J Cancer. 2016 Feb 15;138(4):1024-32. doi: 10.1002/ijc.29848. Epub 2015 Oct 13.

7.

New Approach to Complete Video-assisted Thoracoscopic Lobectomy in T2 and T3 Non-Small Cell Lung Cancer.

Kato M, Onishi H, Furugaki K, Yunotani S, Matsumoto K, Tsuruta N, Nakamura K, Katano M.

Anticancer Res. 2015 Jun;35(6):3585-9.

PMID:
26026131
8.

Intraperitoneal administration of a tumor-associated antigen SART3, CD40L, and GM-CSF gene-loaded polyplex micelle elicits a vaccine effect in mouse tumor models.

Furugaki K, Cui L, Kunisawa Y, Osada K, Shinkai K, Tanaka M, Kataoka K, Nakano K.

PLoS One. 2014 Jul 11;9(7):e101854. doi: 10.1371/journal.pone.0101854. eCollection 2014.

9.

Pulmonary thromboembolism in lung surgery: use of unfractionated heparin.

Yoshida J, Inoue M, Furugaki K, Oyama M, Oozono K.

Asian Cardiovasc Thorac Ann. 2014 Jan;22(1):46-8. doi: 10.1177/0218492313475672. Epub 2013 Oct 22.

PMID:
24585643
10.

Melting curve analysis for mutations of EGFR and KRAS.

Furugaki K, Yasuno H, Iwai T, Moriya Y, Harada N, Fujimoto-Ouchi K.

Anticancer Res. 2014 Feb;34(2):613-21.

PMID:
24510990
11.

Loss of an EGFR-amplified chromosome 7 as a novel mechanism of acquired resistance to EGFR-TKIs in EGFR-mutated NSCLC cells.

Furugaki K, Iwai T, Moriya Y, Harada N, Fujimoto-Ouchi K.

Lung Cancer. 2014 Jan;83(1):44-50. doi: 10.1016/j.lungcan.2013.10.003. Epub 2013 Oct 16.

12.

Block/homo polyplex micelle-based GM-CSF gene therapy via intraperitoneal administration elicits antitumor immunity against peritoneal dissemination and exhibits safety potentials in mice and cynomolgus monkeys.

Ohgidani M, Furugaki K, Shinkai K, Kunisawa Y, Itaka K, Kataoka K, Nakano K.

J Control Release. 2013 May 10;167(3):238-47. doi: 10.1016/j.jconrel.2013.02.006. Epub 2013 Feb 17.

PMID:
23422727
13.

Does antimicrobial homogeneity index influence surgical site infection? A 10-year study in lung, breast, and general surgery.

Yoshida J, Oyama M, Furugaki K, Ishimitsu T, Shinohara M, Miyatake E, Matsuo K.

J Infect Chemother. 2011 Dec;17(6):825-30. doi: 10.1007/s10156-011-0270-x. Epub 2011 Jun 28.

PMID:
21710161
14.

Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models.

Yamashita-Kashima Y, Iijima S, Yorozu K, Furugaki K, Kurasawa M, Ohta M, Fujimoto-Ouchi K.

Clin Cancer Res. 2011 Aug 1;17(15):5060-70. doi: 10.1158/1078-0432.CCR-10-2927. Epub 2011 Jun 23.

15.

Erlotinib inhibits osteolytic bone invasion of human non-small-cell lung cancer cell line NCI-H292.

Furugaki K, Moriya Y, Iwai T, Yorozu K, Yanagisawa M, Kondoh K, Fujimoto-Ohuchi K, Mori K.

Clin Exp Metastasis. 2011 Oct;28(7):649-59. doi: 10.1007/s10585-011-9398-4. Epub 2011 Jun 18.

16.

Esophageal ruptures: triage using the systemic inflammatory response syndrome score.

Furugaki K, Yoshida J, Hokazono K, Emoto T, Nakashima J, Ohyama M, Ishimitsu T, Shinohara M, Matsuo K.

Gen Thorac Cardiovasc Surg. 2011 Mar;59(3):220-4. doi: 10.1007/s11748-010-0617-8. Epub 2011 Mar 30.

PMID:
21448806
17.

Perioperative antimicrobials in chest surgery patients positive for methicillin-resistant Staphylococcus aureus.

Yoshida J, Furugaki K, Oyama M.

Gen Thorac Cardiovasc Surg. 2010 Dec;58(12):657-9. doi: 10.1007/s11748-009-0582-2. Epub 2010 Dec 18.

PMID:
21170640
19.

Bevacizumab improves the delivery and efficacy of paclitaxel.

Yanagisawa M, Yorozu K, Kurasawa M, Nakano K, Furugaki K, Yamashita Y, Mori K, Fujimoto-Ouchi K.

Anticancer Drugs. 2010 Aug;21(7):687-94. doi: 10.1097/CAD.0b013e32833b7598.

PMID:
20559127
20.

Preventing a pitfall: no-knife staplers that require caution during handling.

Yoshida J, Furugaki K.

Gen Thorac Cardiovasc Surg. 2010 Jun;58(6):306-7. doi: 10.1007/s11748-009-0560-8. Epub 2010 Jun 13.

PMID:
20549464
21.

Antitumor activity of erlotinib in combination with gemcitabine in in vitro and in vivo models of KRAS-mutated pancreatic cancers.

Furugaki K, Iwai T, Kondoh K, Moriya Y, Mori K.

Oncol Lett. 2010 Mar;1(2):231-235. Epub 2010 Mar 1.

22.

DNA vaccination with all-trans retinoic acid treatment induces long-term survival and elicits specific immune responses requiring CD4+ and CD8+ T-cell activation in an acute promyelocytic leukemia mouse model.

Furugaki K, Pokorna K, Le Pogam C, Aoki M, Reboul M, Bajzik V, Krief P, Janin A, Noguera ME, West R, Charron D, Chomienne C, Pla M, Moins-Teisserenc H, Padua RA.

Blood. 2010 Jan 21;115(3):653-6. doi: 10.1182/blood-2007-08-109009. Epub 2009 Nov 19.

23.

[A case of drug-induced interstitial pneumonia due to phenytoin].

Okamoto H, Ishimaru T, Ohgami N, Furugaki K, Emoto T, Ekimura M.

Nihon Kokyuki Gakkai Zasshi. 2009 Aug;47(8):758-62. Review. Japanese.

PMID:
19764523
24.

[Chemotherapy for non-small cell lung cancer: split-dose administration of Cisplatin over four consecutive days and Vinorelbine ditartrate].

Furugaki K, Yoshida J, Ogawa R, Nagamatsu I, Miura M, Hokazono K, Umeda S, Shinohara M, Ekimura M, Ishimaru T, Okamoto Y, Ogami N, Nagaoka S, Ebe K, Emoto T, Seto A, Sugihara M, Yukawa J, Matsuo K.

Gan To Kagaku Ryoho. 2009 Feb;36(2):259-63. Japanese.

PMID:
19223742
25.

Interferon-alpha enhances CD317 expression and the antitumor activity of anti-CD317 monoclonal antibody in renal cell carcinoma xenograft models.

Kawai S, Azuma Y, Fujii E, Furugaki K, Ozaki S, Matsumoto T, Kosaka M, Yamada-Okabe H.

Cancer Sci. 2008 Dec;99(12):2461-6. doi: 10.1111/j.1349-7006.2008.00968.x. Epub 2008 Nov 20.

26.

Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells.

Nakano K, Orita T, Nezu J, Yoshino T, Ohizumi I, Sugimoto M, Furugaki K, Kinoshita Y, Ishiguro T, Hamakubo T, Kodama T, Aburatani H, Yamada-Okabe H, Tsuchiya M.

Biochem Biophys Res Commun. 2009 Jan 9;378(2):279-84. doi: 10.1016/j.bbrc.2008.11.033. Epub 2008 Nov 18.

PMID:
19022220
27.

Viral envelope protein gp64 transgenic mouse facilitates the generation of monoclonal antibodies against exogenous membrane proteins displayed on baculovirus.

Saitoh R, Ohtomo T, Yamada Y, Kamada N, Nezu J, Kimura N, Funahashi S, Furugaki K, Yoshino T, Kawase Y, Kato A, Ueda O, Jishage K, Suzuki M, Fukuda R, Arai M, Iwanari H, Takahashi K, Sakihama T, Ohizumi I, Kodama T, Tsuchiya M, Hamakubo T.

J Immunol Methods. 2007 Apr 30;322(1-2):104-17. Epub 2007 Mar 7.

PMID:
17374538
28.

Whole genome association study of rheumatoid arthritis using 27 039 microsatellites.

Tamiya G, Shinya M, Imanishi T, Ikuta T, Makino S, Okamoto K, Furugaki K, Matsumoto T, Mano S, Ando S, Nozaki Y, Yukawa W, Nakashige R, Yamaguchi D, Ishibashi H, Yonekura M, Nakami Y, Takayama S, Endo T, Saruwatari T, Yagura M, Yoshikawa Y, Fujimoto K, Oka A, Chiku S, Linsen SE, Giphart MJ, Kulski JK, Fukazawa T, Hashimoto H, Kimura M, Hoshina Y, Suzuki Y, Hotta T, Mochida J, Minezaki T, Komai K, Shiozawa S, Taniguchi A, Yamanaka H, Kamatani N, Gojobori T, Bahram S, Inoko H.

Hum Mol Genet. 2005 Aug 15;14(16):2305-21. Epub 2005 Jul 6.

PMID:
16000323
29.

SNPs in the promoter of a B cell-specific antisense transcript, SAS-ZFAT, determine susceptibility to autoimmune thyroid disease.

Shirasawa S, Harada H, Furugaki K, Akamizu T, Ishikawa N, Ito K, Ito K, Tamai H, Kuma K, Kubota S, Hiratani H, Tsuchiya T, Baba I, Ishikawa M, Tanaka M, Sakai K, Aoki M, Yamamoto K, Sasazuki T.

Hum Mol Genet. 2004 Oct 1;13(19):2221-31. Epub 2004 Aug 4.

PMID:
15294872
30.

Association of the T-cell regulatory gene CTLA4 with Graves' disease and autoimmune thyroid disease in the Japanese.

Furugaki K, Shirasawa S, Ishikawa N, Ito K, Ito K, Kubota S, Kuma K, Tamai H, Akamizu T, Hiratani H, Tanaka M, Sasazuki T.

J Hum Genet. 2004;49(3):166-8. Epub 2004 Feb 20.

PMID:
14986169
31.

Pyogenic liver abscess after hepatobiliary and pancreatic surgery.

Furugaki K, Chijiiwa K, Ogawa T, Ogawa Y, Tanaka M.

Int Surg. 2001 Jan-Mar;86(1):67-71.

PMID:
11890344
32.

Benign pseudotumorous lesion (fibroangiomyomatous hyperplasia with elastosis) in the gallbladder.

Furugaki K, Satoh H, Shinohara M, Saimura M, Nagai E, Yonemasu H, Kishikawa H.

J Gastroenterol. 2001 Jul;36(7):504-7.

PMID:
11480797
33.

Identification of susceptibility loci for autoimmune thyroid disease to 5q31-q33 and Hashimoto's thyroiditis to 8q23-q24 by multipoint affected sib-pair linkage analysis in Japanese.

Sakai K, Shirasawa S, Ishikawa N, Ito K, Tamai H, Kuma K, Akamizu T, Tanimura M, Furugaki K, Yamamoto K, Sasazuki T.

Hum Mol Genet. 2001 Jun 15;10(13):1379-86.

PMID:
11440990
34.

Infected abdominal aortic aneurysm caused by Campylobacter fetus subspecies fetus: report of a case.

Mii S, Tanaka K, Furugaki K, Sakata H, Katoh H, Mori A.

Surg Today. 1998;28(6):661-4. Review.

PMID:
9681621
35.
36.

Secretory carcinoma of the breast in an elderly woman: report of a case.

Furugaki K, Nagai E, Shinohara M, Saimura M, Ueki T, Toyoshima S, Kishikawa H.

Surg Today. 1998;28(2):219-22.

PMID:
9525017
37.

Inferior vena caval thrombus associated with double neoplasms of the retroperitoneum and kidney: report of a case.

Furugaki K, Yoshida J, Chijiiwa K, Naito S, Tominaga R, Hayashi T, Goto K, Tamiya S, Torisu M, Tanaka M.

Surg Today. 1996;26(8):658-61.

PMID:
8855505

Supplemental Content

Loading ...
Support Center